BioSpace News Archive

Solentim, a life sciences company, has won a place in this year’s Deloitte’s UK Technology Fast 50 list following a 1,106% revenue growth over the past 4 years.

Free emotional-support help line available to people affected by the wildfires

Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.

Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc who held Endocyte securities on the record date November 15, 2018

Pharma Integrates 2018, which took place earlier this week, attracted more than 350 key industry experts to discuss, debate and share insights on critical challenges in the pharmaceutical industry.

Today, the Government of Canada was pleased to receive the preliminary findings and recommendations of Mr. Dainius Pūras, United Nations Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The Government of the State of Quintana Roo has been in contact with the regional U.S. Consulate General in Merida, Mexico, to open a direct dialog with the family of Taylor Meyer, who lost his life in Playa del Carmen on November 9.

AIVITA Biomedical announced today that it has dosed the first two patients in its Phase 2 clinical trial in patients with newly diagnosed glioblastoma.

First-of-its-kind[i] contact lens corrects vision and adapts to changing light conditions to enhance comfort and performance in everyday life

RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, is pleased to announce that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII).